Coya Therapeutics, Inc. (COYA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-01-30

Key Insights

Coya Therapeutics raised approximately $11.1 million in a private placement from key investors Dr. Reddy's Labs and Greenlight Capital.
The company plans to use the proceeds to tech transfer, scale up manufacturing, and accelerate programs for its lead candidate COYA 302.
Coya Therapeutics reiterated its cash runway guidance into the second half of 2027, extending past the projected topline readout for its ALSTARS trial.

Want the newest filings?

This analysis covers the filing from 2026-01-30. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-20

Coya Therapeutics reported a strong cash balance of $46.8 million as of December 31, 2025, which provides a projected cash runway into the second half of 2027.
The company expects to report topline data readout from its ALSTARS Phase 2 trial in the first quarter of 2027, a key milestone for the company's pipeline.
As an emerging growth company, Coya Therapeutics may choose to take advantage of the extended transition period for complying with new or revised financial accounting standards.

Filed: 2026-01-08

Coya Therapeutics, an emerging biotech company, reported positive results from a proof-of-concept study evaluating a combination therapy of low-dose IL-2 and CTLA4-Ig in 9 patients with Frontotemporal Dementia (FTD). The study demonstrated increased Treg numbers and function, as well as cognitive function stability, over the 22-week treatment period.
The safety profile of the combination therapy was favorable, with the most common adverse event being mild erythema at the injection site, and no serious adverse events reported.
The stable cognitive function, as measured by MOCA and CDR-FTLD scores, suggests the potential of this combination therapy to slow the progression of cognitive decline in FTD patients, an important unmet medical need.

Other reports for Coya Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.